Login to Your Account

Checkmate lines up chess pieces, eyes pivotal program with $27M series B

By Marie Powers
News Editor

Monday, June 19, 2017

Checkmate Pharmaceuticals Inc. might be the only immuno-oncology (I-O) company that's not attending the BIO International Convention in San Diego. Instead, the Cambridge, Mass.-based firm will spend the week plotting the next moves to advance its only asset, CMP-001, after completing a $27 million series B preferred financing led by new investor F-Prime Capital Partners.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription